Difference between revisions of "Template:Ion channel modulators"

From blackwiki
Jump to navigation Jump to search
imported>Edgar181
 
(54 intermediate revisions by 14 users not shown)
Line 1: Line 1:
 
{{Navbox
 
{{Navbox
 
  | name = Ion channel modulators
 
  | name = Ion channel modulators
−
  | title = [[Ion channel modulator]]s
+
  | title = [[Channel modulator|Ion channel modulator]]s
 
  | state = {{{state<includeonly>|collapsed</includeonly>}}}
 
  | state = {{{state<includeonly>|collapsed</includeonly>}}}
 
  | listclass = hlist
 
  | listclass = hlist
 
  | groupstyle = text-align:center;
 
  | groupstyle = text-align:center;
  
−
  | group1 = [[Calcium channel|Calcium]] (Ca<sup>2+</sup>)
+
  | group1 = [[Calcium channel|Calcium]]
 
  | list1 = {{Navbox|child
 
  | list1 = {{Navbox|child
 
  | groupstyle = text-align:center;
 
  | groupstyle = text-align:center;
 +
| groupwidth = 5em;
  
−
   | group1 = [[Calcium channel blocker|Blocker]]s
+
   | group1 = {{abbrlink|VDCCs|Voltage-dependent calcium channels}}
−
  | list1 =
+
  | list1 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Calcium channel blocker|Blocker]]s
 +
    | list1 =
 
* '''[[L-type calcium channel|L-type-selective]]:''' ''[[Dihydropyridine]]s:'' [[Amlodipine]]
 
* '''[[L-type calcium channel|L-type-selective]]:''' ''[[Dihydropyridine]]s:'' [[Amlodipine]]
 
* [[Aranidipine]]
 
* [[Aranidipine]]
Line 33: Line 39:
 
* [[Levniguldipine]]
 
* [[Levniguldipine]]
 
* [[Manidipine]]
 
* [[Manidipine]]
−
* [[Mepirodipine]]
+
* [[Barnidipine|Mepirodipine]]
 
* [[Mesudipine]]
 
* [[Mesudipine]]
 
* [[Nicardipine]]
 
* [[Nicardipine]]
Line 47: Line 53:
 
* [[Palonidipine]]
 
* [[Palonidipine]]
 
* [[Pranidipine]]
 
* [[Pranidipine]]
−
* [[Ryodipine]]
+
* [[Riodipine|Ryodipine (riodipine)]]
 
* [[Sagandipine]]
 
* [[Sagandipine]]
 
* [[Sornidipine]]
 
* [[Sornidipine]]
Line 57: Line 63:
 
* [[Iprotiazem]]
 
* [[Iprotiazem]]
 
* [[Nictiazem]]
 
* [[Nictiazem]]
−
* [[Siratiazem]]; ''[[Phenylalkylamine]]s:'' [[Anipamil]]
+
* [[Siratiazem]]; ''[[Arylalkylamine|Phenylalkylamine]]s:'' [[Anipamil]]
 
* [[Dagapamil]]
 
* [[Dagapamil]]
 
* [[Devapamil]]
 
* [[Devapamil]]
Line 78: Line 84:
 
* [[Fantofarone]]
 
* [[Fantofarone]]
 
* [[SR-33805]]<!--allosteric blocker-->
 
* [[SR-33805]]<!--allosteric blocker-->
 +
* [[Tetrahydropalmatine]]
  
 
* '''[[N-type calcium channel|N-type-selective]]:''' [[ω-Conotoxin]]s
 
* '''[[N-type calcium channel|N-type-selective]]:''' [[ω-Conotoxin]]s
Line 149: Line 156:
 
* [[Elpetrigine]]
 
* [[Elpetrigine]]
 
* [[Ethadione]]
 
* [[Ethadione]]
 +
* [[Alcohol (drug)|Ethanol (alcohol)]]
 
* [[Ethosuximide]]
 
* [[Ethosuximide]]
 
* [[Fasudil]]
 
* [[Fasudil]]
 
* [[Fendiline]]
 
* [[Fendiline]]
 
* [[Fostedil]]
 
* [[Fostedil]]
 +
* [[Imepitoin]]
 
* [[JTV-519]]
 
* [[JTV-519]]
 
* [[Lidoflazine]]
 
* [[Lidoflazine]]
Line 165: Line 174:
 
* [[Paramethadione]]
 
* [[Paramethadione]]
 
* [[Phensuximide]]
 
* [[Phensuximide]]
−
* [[Pinaverium]]
+
* [[Pinaverium bromide]]
 
* [[Prenylamine]]
 
* [[Prenylamine]]
 
* [[Rhynchophylline]]
 
* [[Rhynchophylline]]
Line 172: Line 181:
 
* [[Sipatrigine]]
 
* [[Sipatrigine]]
 
* [[Terodiline]]
 
* [[Terodiline]]
−
* [[Tetrahydropalmatine]]
 
 
* [[Tetrandrine]]
 
* [[Tetrandrine]]
 
* [[Tolperisone]]
 
* [[Tolperisone]]
Line 178: Line 186:
 
* [[Valperinol]]
 
* [[Valperinol]]
  
−
   | group2 = [[Calcium channel opener|Openers]]
+
   | group2 = [[Calcium channel opener|Activator]]s
 
   | list2 =
 
   | list2 =
 
* '''[[L-type calcium channel|L-type-selective]]:''' [[Bay K8644]]
 
* '''[[L-type calcium channel|L-type-selective]]:''' [[Bay K8644]]
 +
 +
    }}
  
 
}}
 
}}
  
−
  | group2 = [[Potassium channel|Potassium]] (K<sup>+</sup>)
+
  | group2 = [[Potassium channel|Potassium]]
 
  | list2 = {{Navbox|child
 
  | list2 = {{Navbox|child
 
  | groupstyle = text-align:center;
 
  | groupstyle = text-align:center;
 +
| groupwidth = 5em;
  
−
   | group1 = [[Potassium channel blocker|Blocker]]s
+
   | group1 = {{abbrlink|VGKCs|Voltage-gated potassium channels}}
−
  | list1 =
+
  | list1 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Potassium channel blocker|Blocker]]s
 +
    | list1 =
 
* [[3,4-Diaminopyridine|3,4-Diaminopyridine (amifampridine)]]
 
* [[3,4-Diaminopyridine|3,4-Diaminopyridine (amifampridine)]]
 
* [[4-Aminopyridine|4-Aminopyridine (fampridine/dalfampridine)]]
 
* [[4-Aminopyridine|4-Aminopyridine (fampridine/dalfampridine)]]
Line 207: Line 223:
 
* [[E-4031]]
 
* [[E-4031]]
 
* [[Hanatoxin]]
 
* [[Hanatoxin]]
 +
* [[HgeTx1]]
 +
* [[HsTx1]]
 
* [[Ibutilide]]
 
* [[Ibutilide]]
 
* [[Inakalant]]
 
* [[Inakalant]]
 
* [[Kaliotoxin]]
 
* [[Kaliotoxin]]
 
* [[Linopirdine]]
 
* [[Linopirdine]]
 +
* [[Lolitrem B]]
 
* [[Maurotoxin]]
 
* [[Maurotoxin]]
 
* [[Nifekalant]]
 
* [[Nifekalant]]
Line 216: Line 235:
 
* [[Paxilline]]
 
* [[Paxilline]]
 
* [[Pinokalant]]
 
* [[Pinokalant]]
 +
* [[Quinidine]]
 
* [[ShK-186]]<!--Kv1.3-selective-->
 
* [[ShK-186]]<!--Kv1.3-selective-->
 
* [[Sotalol]]
 
* [[Sotalol]]
Line 223: Line 243:
 
* [[Vernakalant]]
 
* [[Vernakalant]]
  
−
* '''[[G protein-coupled inwardly-rectifying potassium channel|GIRK]] blockers:''' [[Tipepidine]]
+
* '''[[hERG]] (KCNH2, K<sub>v</sub>11.1)-specific:''' [[Ajmaline]]
−
 
 
−
* '''[[hERG]] blockers:''' [[Ajmaline]]
 
 
* [[Amiodarone]]
 
* [[Amiodarone]]
 
* [[AmmTX3]]
 
* [[AmmTX3]]
Line 254: Line 272:
 
* [[PNU-282,987]]
 
* [[PNU-282,987]]
 
* [[Promethazine]]
 
* [[Promethazine]]
 +
* [[Quinidine]]
 +
* [[Ranolazine]]
 
* [[Roxithromycin]]
 
* [[Roxithromycin]]
 
* [[Sertindole]]
 
* [[Sertindole]]
Line 265: Line 285:
 
* [[Vernakalant]]
 
* [[Vernakalant]]
  
−
  | group2 = [[Potassium channel opener|Openers]]
+
* '''[[KCNQ|KCNQ (K<sub>v</sub>7)]]-specific:''' [[Linopirdine]]
−
  | list2 =
+
* [[XE-991]]
−
* '''[[ATP-sensitive potassium channel|K<sub>ATP</sub>]] openers:''' [[Aprikalim]]
+
* [[Ssm spooky toxin|Spooky toxin (SsTx)]]
 +
 
 +
    | group2 = [[Potassium channel opener|Activator]]s
 +
    | list2 =
 +
* '''[[KCNQ|KCNQ (K<sub>v</sub>7)]]-specific:''' [[Flupirtine]]
 +
* [[Retigabine]]
 +
 
 +
    }}
 +
 
 +
  | group2 = {{abbrlink|IRKs|Inwardly rectifying potassium channel}}
 +
  | list2 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Potassium channel blocker|Blocker]]s
 +
    | list1 =
 +
* '''{{abbrlink|K<sub>ATP</sub>|ATP-sensitive potassium channel}}-specific:''' [[Acetohexamide]]
 +
* [[Carbutamide]]
 +
* [[Chlorpropamide]]
 +
* [[Glibenclamide|Glibenclamide (glyburide)]]
 +
* [[Glibornuride]]
 +
* [[Glicaramide]]
 +
* [[Gliclazide]]
 +
* [[Glimepiride]]
 +
* [[Glipizide]]
 +
* [[Gliquidone]]
 +
* [[Glisoxepide]]
 +
* [[Glyclopyramide]]
 +
* [[Glycyclamide]]
 +
* [[Metahexamide]]
 +
* [[Mitiglinide]]
 +
* [[Nateglinide]]
 +
* [[Repaglinide]]
 +
* [[Tolazamide]]
 +
* [[Tolbutamide]]
 +
 
 +
* '''{{abbrlink|GIRK|G protein-coupled inwardly-rectifying potassium channel}}-specific:''' [[Barium]]
 +
* [[Caramiphen]]
 +
* [[Cloperastine]]
 +
* [[Clozapine]]
 +
* [[Dextromethorphan]]
 +
* [[Ethosuximide]]
 +
* [[Ifenprodil]]
 +
* [[Tertiapin]]
 +
* [[Tipepidine]]
 +
 
 +
    | group2 = [[Potassium channel opener|Activator]]s
 +
    | list2 =
 +
* '''{{abbrlink|K<sub>ATP</sub>|ATP-sensitive potassium channel}}-specific:''' [[Aprikalim]]
 
* [[Bimakalim]]
 
* [[Bimakalim]]
 
* [[Cromakalim]]
 
* [[Cromakalim]]
 +
* [[Diazoxide]]
 
* [[Emakalim]]
 
* [[Emakalim]]
 
* [[Levcromakalim]]
 
* [[Levcromakalim]]
 
* [[Mazokalim]]
 
* [[Mazokalim]]
−
* [[Rilmakalim]]
 
−
* [[Sarakalim]]
 
−
 
−
* '''Others:''' [[Diazoxide]]
 
−
* [[Flupirtine]]
 
 
* [[Minoxidil]]
 
* [[Minoxidil]]
 
* [[Naminidil]]
 
* [[Naminidil]]
 
* [[Nicorandil]]
 
* [[Nicorandil]]
 
* [[Pinacidil]]
 
* [[Pinacidil]]
−
* [[Retigabine]]
+
* [[Rilmakalim]]
−
* [[Rottlerin]]
+
* [[Sarakalim]]
 +
 
 +
* '''{{abbrlink|GIRK|G protein-coupled inwardly-rectifying potassium channel}}-specific:''' [[ML-297|ML-297 (VU0456810)]]
 +
 
 +
  }}
 +
 
 +
  | group3 = {{abbrlink|K<sub>Ca</sub>|Calcium-activated potassium channel}}
 +
  | list3 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Potassium channel blocker|Blocker]]s
 +
    | list1 =
 +
* '''[[BK channel|BK<sub>Ca</sub>]]-specific:''' [[Alcohol (drug)|Ethanol (alcohol)]]
 +
* [[GAL-021]]
 +
 
 +
    | group2 = [[Potassium channel opener|Activator]]s
 +
    | list2 =
 +
* '''[[BK channel|BK<sub>Ca</sub>]]-specific:''' [[Flufenamic acid]]
 +
* [[Meclofenamic acid]]
 +
* [[Niflumic acid]]
 +
* [[Nimesulide]]
 +
* [[Rottlerin|Rottlerin (mallotoxin)]]
 +
* [[Tolfenamic acid]]
 +
 
 +
  }}
 +
 
 +
  | group4 = {{abbrlink|K2Ps|Tandem pore domain potassium channel}}
 +
  | list4 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Potassium channel blocker|Blocker]]s
 +
    | list1 =
 +
* [[12-O-Tetradecanoylphorbol-13-acetate]]
 +
* [[Arachidonic acid]]
 +
* [[Fluoxetine]]
 +
* [[Norfluoxetine]]
 +
 
 +
    | group2 = [[Potassium channel opener|Activator]]s
 +
    | list2 =
 +
* [[Riluzole]]
 +
 
 +
  }}
  
 
}}
 
}}
  
−
  | group3 = [[Sodium channel|Sodium]] (Na<sup>+</sup>)
+
  | group3 = [[Sodium channel|Sodium]]
 
  | list3 = {{Navbox|child
 
  | list3 = {{Navbox|child
 
  | groupstyle = text-align:center;
 
  | groupstyle = text-align:center;
 +
| groupwidth = 5em;
 +
 +
  | group1 = {{abbrlink|VGSCs|Voltage-gated sodium channels}}
 +
  | list1 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 +
    | group1 = [[Sodium channel blocker|Blocker]]s
 +
    | list1 =
 +
* ''Antianginals:'' [[Ranolazine]]
  
−
  | group1 = [[Sodium channel blocker|Blocker]]s
+
* ''Antiarrhythmics (class I):'' [[Ajmaline]]
−
  | list1 =
 
−
* '''[[Voltage-gated sodium channel|VGSC]] blockers:''' ''Antiarrhythmics (class I):'' [[Ajmaline]]
 
 
* [[Aprindine]]
 
* [[Aprindine]]
 
* [[Disopyramide]]
 
* [[Disopyramide]]
Line 310: Line 425:
 
* [[Quinidine]]
 
* [[Quinidine]]
 
* [[Sparteine]]
 
* [[Sparteine]]
−
* [[Tocainide]]; ''Anticonvulsants:'' [[Acetylpheneturide]]
+
* [[Tocainide]]
 +
 
 +
* ''Anticonvulsants:'' [[Acetylpheneturide]]
 
* [[Carbamazepine]]
 
* [[Carbamazepine]]
 
* [[Cenobamate]]
 
* [[Cenobamate]]
Line 335: Line 452:
 
* [[Valproic acid]]
 
* [[Valproic acid]]
 
* [[Valpromide]]
 
* [[Valpromide]]
−
* [[Zonisamide]]; ''Diuretics:'' [[Amiloride]]
+
* [[Zonisamide]]
−
* [[Benzamil]]
+
 
−
* [[Triamterene]]; ''Local anesthetics:'' [[3-(p-Fluorobenzoyloxy)tropane|''p''FBT]]
+
* ''Local anesthetics:'' [[3-(p-Fluorobenzoyloxy)tropane|''p''FBT]]
 
* [[Amylocaine]]
 
* [[Amylocaine]]
 
* [[Articaine]]
 
* [[Articaine]]
Line 365: Line 482:
 
* [[Risocaine]]
 
* [[Risocaine]]
 
* [[Tetracaine]]
 
* [[Tetracaine]]
−
* [[Trimecaine]]; ''Analgesics:'' [[AZD-3161]]
+
* [[Trimecaine]]
 +
 
 +
* ''Analgesics:'' [[AZD-3161]]
 
* [[DSP-2230]]
 
* [[DSP-2230]]
 
* [[Funapide]]
 
* [[Funapide]]
Line 374: Line 493:
 
* [[Ralfinamide]]
 
* [[Ralfinamide]]
 
* [[Raxatrigine]]
 
* [[Raxatrigine]]
−
* [[RG7893|RG7893 (GDC-0287)]]; ''Toxins:'' [[Conotoxin]]s
+
* [[RG7893|RG7893 (GDC-0287)]]
 +
 
 +
* ''Toxins:'' [[Conotoxin]]s
 
* [[Neosaxitoxin]]
 
* [[Neosaxitoxin]]
 
* [[Saxitoxin]]
 
* [[Saxitoxin]]
−
* [[Tetrodotoxin]]; ''Others:'' [[Buprenorphine]]
+
* [[Tetrodotoxin]]
 +
* [[Zetekitoxin AB]]
 +
 
 +
* ''Others:'' [[Buprenorphine]]
 
* [[Evenamide]]
 
* [[Evenamide]]
−
* [[Menthol]]
+
* [[Menthol]] ([[Mentha|mint]])
 
* [[Safinamide]]
 
* [[Safinamide]]
 
* [[Tricyclic antidepressant]]s
 
* [[Tricyclic antidepressant]]s
  
−
   | group2 = [[Sodium channel opener|Openers]]
+
   | group2 = [[Sodium channel opener|Activator]]s
 
   | list2 =
 
   | list2 =
−
* '''[[Voltage-gated sodium channel|VGSC]] openers:''' [[Atracotoxin]]s ([[Robustoxin]], [[Versutoxin]])
+
* [[Aconitine]]
 +
* Atracotoxins ([[omega-Atracotoxin|ω-Atracotoxin]], [[Robustoxin]], [[Versutoxin]])
 +
* [[Batrachotoxin]]
 
* [[Ciguatoxin]]s
 
* [[Ciguatoxin]]s
 +
* [[Grayanotoxin]]s
 +
* [[Poneratoxin]]
 +
 +
  }}
 +
 +
  | group2 = {{abbrlink|ENaC|Epithelial sodium channel}}
 +
  | list2 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
  
−
* '''[[Epithelial sodium channel|ENaC]] openers:''' [[Solnatide]]
+
    | group1 = [[Sodium channel blocker|Blocker]]s
 +
    | list1 =
 +
* [[Amiloride]]
 +
* [[Benzamil]]
 +
* [[Triamterene]]
 +
 
 +
    | group2 = [[Sodium channel opener|Activator]]s
 +
    | list2 =
 +
* [[Solnatide]]
 +
 
 +
  }}
 +
 
 +
  | group3 = {{abbrlink|ASICs|Acid-sensing ion channel}}
 +
  | list3 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 
 +
    | group1 = [[Sodium channel blocker|Blocker]]s
 +
    | list1 =
 +
* [[A-317567]]
 +
* [[Amiloride]]
 +
* [[Aspirin]]
 +
* [[Ibuprofen]]
 +
* [[PcTX1]]
 +
 
 +
    | group2 = [[Sodium channel opener|Activator]]s
 +
    | list2 =
 +
 
 +
  }}
  
 
}}
 
}}
  
−
  | group4 = [[Chloride channel|Chloride]] (Cl<sup>−</sup>)
+
  | group4 = [[Chloride channel|Chloride]]
 
  | list4 = {{Navbox|child
 
  | list4 = {{Navbox|child
 
  | groupstyle = text-align:center;
 
  | groupstyle = text-align:center;
 +
| groupwidth = 5em;
  
−
   | group1 = [[Chloride channel blocker|Blocker]]s
+
   | group1 ={{abbrlink|CaCCs|Calcium-activated chloride channel}}
−
   | list1 =
+
  | list1 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
   | groupwidth = 5em;
  
−
* [[Bumetanide]]
+
    | group1 = [[Chloride channel blocker|Blocker]]s
−
* [[DIDS]]
+
    | list1 =
 +
* [[Crofelemer]]<!--ANO1-->
 +
* [[DIDS]]<!--ANO1-->
 +
* [[Ethacrynic acid]]
 
* [[Flufenamic acid]]
 
* [[Flufenamic acid]]
 +
* [[Fluoxetine]]
 
* [[Furosemide]]
 
* [[Furosemide]]
 +
* [[Glibenclamide]]
 +
* [[Mefloquine]]
 +
* [[Mibefradil]]
 +
* [[Niflumic acid]]
 +
 +
    | group2 = [[Chloride channel opener|Activator]]s
 +
    | list2 =
 +
* [[Carbachol]]<!--ANO1-->
 +
 +
  }}
 +
 +
  | group2 = {{abbrlink|CFTR|Cystic fibrosis transmembrane conductance regulator}}
 +
  | list2 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 +
    | group1 = [[Chloride channel blocker|Blocker]]s
 +
    | list1 =
 
* [[Glibenclamide]]
 
* [[Glibenclamide]]
 
* [[Lonidamine]]
 
* [[Lonidamine]]
 +
* [[Piretanide]]
 +
 +
    | group2 = [[Chloride channel opener|Activator]]s
 +
    | list2 =
 +
* [[1,7-Phenanthroline]]
 +
* [[1,10-Phenanthroline]]
 +
* [[4,7-Phenanthroline]]
 +
* [[7,8-Benzoquinoline]]
 +
* [[Ivacaftor]]
 +
* [[Phenanthridine]]
 +
 +
  }}
 +
 +
  | group3 = Unsorted
 +
  | list3 = {{Navbox|child
 +
  | groupstyle = text-align:center;
 +
  | groupwidth = 5em;
 +
 +
    | group1 = [[Chloride channel blocker|Blocker]]s
 +
    | list1 =
 +
* [[Bumetanide]]
 +
* [[Flufenamic acid]]
 
* [[Meclofenamic acid]]
 
* [[Meclofenamic acid]]
 
* [[Mefenamic acid]]
 
* [[Mefenamic acid]]
 
* [[Mepacrine]]
 
* [[Mepacrine]]
 
* [[Niflumic acid]]
 
* [[Niflumic acid]]
−
* [[Piretanide]]
 
 
* [[Talniflumate]]
 
* [[Talniflumate]]
 
* [[Tolfenamic acid]]
 
* [[Tolfenamic acid]]
 
* [[Trifluoperazine]]
 
* [[Trifluoperazine]]
  
−
  | group2 = [[Chloride channel opener|Openers]]
+
    | group2 = [[Chloride channel opener|Activator]]s
−
   | list2 =
+
    | list2 =
−
* '''[[Cystic fibrosis transmembrane conductance regulator|CFTR]] openers:''' [[1,7-Phenanthroline]]
+
 
−
* [[1,10-Phenanthroline]]
+
   }}
−
* [[4,7-Phenanthroline]]
+
 
−
* [[7,8-Benzoquinoline]]
+
}}
−
* [[Phenanthridine]]
+
 
 +
| group5 = Others
 +
| list5 = {{Navbox|child
 +
| groupstyle = text-align:center;
 +
| groupwidth = 5em;
 +
 
 +
  | group1 = {{abbrlink|TRPs|Transient receptor potential channels}}
 +
  | list1 =
 +
* See [[Template:Transient receptor potential channel modulators|here]] instead.
 +
 
 +
  | group2 = {{abbrlink|LGICs|Ligand gated ion channels}}
 +
  | list2 =
 +
* See [[Template:Pharmacomodulation|here]] instead.
  
 
  }}
 
  }}
  
−
  | belowstyle = background: transparent; padding: 0px;
+
  | below = '''''See also:''' [[Template:Receptor modulators|Receptor/signaling modulators]] • [[Template:Transient receptor potential channel modulators|Transient receptor potential channel modulators]]''
−
| below = {{Vascular navs}}
 
  
 
}}<noinclude>
 
}}<noinclude>

Latest revision as of 13:24, 22 July 2019

Initial visibility: currently defaults to autocollapse

To set this template's initial visibility, the |state= parameter may be used:

  • |state=collapsed: {{Ion channel modulators|state=collapsed}} to show the template collapsed, i.e., hidden apart from its title bar
  • |state=expanded: {{Ion channel modulators|state=expanded}} to show the template expanded, i.e., fully visible
  • |state=autocollapse: {{Ion channel modulators|state=autocollapse}}
    • shows the template collapsed to the title bar if there is a {{navbar}}, a {{sidebar}}, or some other table on the page with the collapsible attribute
    • shows the template in its expanded state if there are no other collapsible items on the page

If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.

Retrieved from "https://blackwiki.org/index.php?title=Template:Ion_channel_modulators&oldid=6460516"